Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

09 February 2021

4 principles for urgent pharma action to combat COVID-19

Drawing on the findings from the 2021 Access to Medicine Index, the Norwegian government, which co-chairs the Facilitation Council of the ACT-Accelerator, has proposed four principles for urgent pharma action to ensure equity to COVID-19 vaccines and treatments in low- and middle-income countries (LMICs).

In this piece, authors Dag-Inge Ulstein, Minister of International Development for the Norwegian Government, and John-Arne Røttingen, Ambassador for Global Health for the Norwegian Ministry of Foreign Affairs, use findings from the 2021 Access to Medicine Index to identify four areas where pharmaceutical companies can take urgent action to ensure equal access to COVID-19 vaccines and treatments:

  1. File for registration rapidly, widely and on the basis of the most rigorous standards

  2.  Price health technologies fairly

  3. Expand production and supply capacity

  4. Transparency from all actors

Read the full article here. 

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved